Loading patent…
AssigneeVentana Medical Systems, Inc.
InventorsMichael Barnes, June F. Clements, Thomas Grogan, Hiro Nitta, Esteban Roberts, Crystal Schemp, Shalini Singh, Penny Towne
Estimating the term…
Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.
An immunohistochemical method comprising:
Dependencies are inferred from the claim text.